Anti-Müllerian hormone in health and disease: a review


  • Mangala Sirsikar Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, #82, EPIP Area, Nallurhalli, Whitefield, Bangalore-560066, Karnataka
  • Venkata Bharat Kumar Pinnelli Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, #82, EPIP Area, Nallurhalli, Whitefield, Bangalore-560066, Karnataka
  • Shrabani Mohanty Department of Biochemistry, Vydehi Institute of Medical Sciences and Research Centre, #82, EPIP Area, Nallurhalli, Whitefield, Bangalore-560066, Karnataka
  • Jayashankar C. A. Department of General Medicine, Vydehi Institute of Medical Sciences and Research Centre, #82, EPIP Area, Nallurhalli, Whitefield, Bangalore-560066, Karnataka



Anti-Müllerian hormone, Ovarian aging, Polycystic ovary syndrome, Obesity, Assisted reproduction, Tumor marker


Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein, member of the transforming growth factor β family of growth and differentiation factors. In the ovary, AMH has an inhibitory effect on primordial follicle recruitment as well as on the responsiveness of growing follicles to follicle-stimulating hormone (FSH). The ovary-specific expression pattern in granulosa cells of growing non-selected follicles makes AMH an ideal marker for the size of the ovarian follicle pool.  AMH levels accurately reflect the ovarian follicular reserve and could, therefore, be considered as an extremely sensitive marker of ovarian aging and a valuable tool in the diagnosis and the recognition of recurrence of granulosa cell tumors. Furthermore, AMH could be a surrogate diagnostic marker of polycystic ovary syndrome in cases in which ultrasonographic examination is not possible. Additionally AMH evaluation is of clinical importance in predicting the success of in vitro fertilization (IVF). Special reference is made to the possible implications of AMH in the pathogenesis of polycystic ovary syndrome and the relationship between AMH and obesity. AMH also plays important role in evaluation of infants with ambiguous genitalia and other intersex conditions. This article is a review of the clinical usefulness of AMH evaluation in the fields of gynecological endocrinology, menopause, gynecological oncology and assisted reproduction and also in pediatric patients.


Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986;45:685e98.

Itman C, Mendis S, Barakat B, Loveland LK. All in the family: TGF β family action in testes development. Reproduction. 2006;132:233-6.

Visser JA de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1-9.

Massague J, Attisano L, Wrana JL. The TGF β family and its composite receptors. Trends Cell Biol. 1994;4:172-8.

Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77-83.

Rajperts-de Meyts E, Jorgensen N, Graem N, Muller J, Cate RL, Skakkebaek NE. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84:3836-44.

Cook CL, Siow Y, Taylor S, Fallat M. Serum Müllerian inhibiting substance levels during normal menstrual cycles. FertilSteril. 2000;73:859-61.

Themmen AP. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr. 2005;34:18-21.

Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kuman TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891-9.

Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Human Reprod. 2008;23:1359-65.

Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, et al. Serum antimu¨llerian hormone in healthy premenopausal women. Fertil Steril. 2011;95:2718-21.

Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of Antimullerian hormone during pregnancy: relationship with maternal adiposity, insulin and adiponectin. FertilSteril. 2010;93:1356-8.

Lutterodt M, Byskov AG, Skouby SO, Tabor A, Yding Andersen C. Anti-Mullerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online. 2009;18:694-9.

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. Journal of Clinical Endocrinology and Metabolism. 2003;88:5957-62.

Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa cell production of anti Mullerian hormone is increased in polycystic ovaries. J ClinEndocrinolMetab. 2007;92:240-5.

Agarwal SK, Judd HL, Magoffin DA. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 1996;81:3686-91.

Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Journal of Clinical Endocrinology and Metabolism. 1999;28:361-78.

Siow Y, Kives S, Hertweek P, Perlman S, Fallat ME. 2005 Serum Müllerian inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. FertilSteril. 2005;84:938-44.

Diamanti-Kandarakis E, Piouka A, Livadas S, Papavassiliou AG, Panidis D. Anti-Müllerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol. 2009;160:847-53.

Rich-Edwards JW, Spiegelman D, Garland M, Hertzmark E, Hunter DJ, Colditz GA, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002;13:184-90.

Gracia CR, Freeman EW, Sammel MD, Lin H, Nelson DB. The relationship between obesity and race on inhibin B during the menopause transition. Menopause 2005; 12:559-66.

Katsikis I, Karkanaki A, Misichronis G, DelkosD, Kandaraki EA, Panidis D. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. EurJ bstet Gynecol Reprod Biol. 2011;156:181-5.

La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al, Anti- Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113-30.

Fanchin R, Mendez Lozano DH, Frydman N. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J ClinEndocrinol Metab. 2007;92:1796-802.

Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159-68.

Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-Mu¨llerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23:160-7.

Stephen AE, Pearsoll LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purifiedMüllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res. 2002;8:2640-6.

Rey R, Sabourin JC, Venara M. Anti-Müllerian hormone is specific marker of sertoli -and granulose-cell origin in gonadal tumors. Hum Pathol. 2000;31:1202-3.

Rajpert-De Meyts E, Jørgensen N, Graem N, Mu¨ller J, Cate RL, Skakkebaek NE. Expression of anti-Mu¨llerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J ClinEndocrinolMetab. 1999;84:3836-44.

Rouiller-Fabre V, Carmona S, Merhi RA, Cate R, Habert R, Vigier B. Effect of anti-Mullerian hormone on Sertoli and Leydig cell functions in fetal and immature rats. Endocrinology. 1998;139:1213-20.

Rey R, Mebarki F, Forest MG, Mowszowicz I, Cate RL, Morel Y, et al. Anti-mu¨llerian hormone in children with androgen insensitivity. J Clin Endocrinol Metab. 1994;79:960-4.

Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, et al. Measurements of serum mu¨llerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med. 1997;336:1480-6.

Fe´nichel P, Rey R, Poggioli S, Donzeau M, Chevallier D, Pointis G. Anti-Mu¨llerian hormone as a seminal marker for spermatogenesis in non-obstructive azoospermia. Hum Reprod. 1999;14:2020-4.

Appasamy M, Muttukrishna S, Pizzey AR, Ozturk O, Groome NP, Serhal P, et al. Relationship between male reproductive hormones, sperm DNA damage and markers of oxidative stress in infertility. Reprod Biomed Online. 2007;14:159-65.

Tu¨ttelmann F, Dykstra N, Themmen AP, Visser JA, Nieschlag E, Simoni M. Anti-Mu¨llerian hormone in men with normal and reduced sperm concentration and men with maldescended testes. FertilSteril. 2009;91:1812-9.

Muttukrishna S, Yussoff H, Naidu M, Barua J, Arambage K, Suharjono H, et al. Serum anti-Mu¨llerian hormone and inhibin B in disorders of spermatogenesis. FertilSteril. 2007;88:516-8.

Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles – implications for individualization of therapy. Human Reprod. 2007;22:2414-21.




How to Cite

Sirsikar, M., Pinnelli, V. B. K., Mohanty, S., & C. A., J. (2017). Anti-Müllerian hormone in health and disease: a review. International Journal of Research in Medical Sciences, 4(7), 2514–2520.



Review Articles